beyondthedish.wordpress.com
Geron Corporation Announces Phase II Trial for Brain-Specific Anticancer Drug GNR1005
After a successful completion of a Phase I study, Geron Corporation announces the initiation of a phase II trial for its GRN1005 anticancer drug. This drug was designed to specifically treat tumors…